Skip to navigation Skip to content



About this Medication
  • Brand Name: Lemtrada® (lem-TRA-da)
  • Chemical Name: alemtuzumab (ay-lem-TU-zoo-mab)
  • Usage in MS: Disease-Modifying Agent
  • Generic Available: No

This medication is given by IV infusion.


Lemtrada® is a humanized monoclonal antibody directed at CD52 (a protein on the surface 
of immune cells).  
Lemtrada is approved by the FDA for the treatment of relapsing forms of multiple sclerosis, to include relapsing remitting disease and active secondary progressive disease, in adults. Because of Lemtrada’s safety profile, the FDA recommends that this medication generally be reserved for people who have had an inadequate response to two or more MS therapies.
Click here to read the Lemtrada Prescribing Information for healthcare professionals.
Click here to read the Lemtrada Medication Guide for patients.


Call Genzyme at 1- 855-MSOne2One (1-855-676-6326)

Financial Assistance Program

Lemtrada Copay Program
1- 855-MSOne2One (1-855-676-6326)


What You Need To Know About Lemtrada™

This video was created in May, 2015 and features Gabriel Pardo, MD and Kathleen Costello, MSCN. Information is accurate as of then. To learn more about Lemtrada™ and other disease modifying treatment options, download the Consensus on Disease-Modifying Therapies.

Watch Now


© 2024 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.